NORGINE LAUNCHES MOVICOL READY TO TAKE MACROGOL 3350 SODIUM HYDROGEN CARBONATE SODIUM CARBONATE POTASSIUM CHLORIDE IN THE UNITED KINGDOM

Back to media releases
Next media release
01 September 2016

NORGINE LAUNCHES MOVICOL® READY TO TAKE (MACROGOL 3350, SODIUM HYDROGEN CARBONATE, SODIUM CARBONATE, POTASSIUM CHLORIDE) IN THE UNITED KINGDOM

Reinforcing Norgine’s commitment to improving patient care.

 

LONDON, UK, Thursday 1 September 2016, 07:00 BST. Norgine today announced the launch of MOVICOL® Ready to Take in the United Kingdom, a treatment for  constipation and faecal impaction in adults and adolescents (12 years and above).[1]

MOVICOL® Ready to Take is a ready mixed, pocket size dose that can be easily incorporated into daily life. This new formulation offers patients a discrete and convenient way to take their laxative. The product is available from today (1 September 2016) and is priced at £2.35 for a box of 10 stick packs, and £7.45 for a box of 30, the same price as other similar formulations in the range.

For patient information please contact 01895 826606.

Bob Cuffe, General Manager, UK & ROI at Norgine said: “This launch is important to patients in the UK as MOVICOL® Ready to Take offers trusted efficacy, in a new convenient formulation.”

Norgine launched in Germany in June 2016 and anticipates further launches through its European infrastructure later on this year and in 2017.

Ends

Notes to Editors:

 

About Norgine

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine’s total revenue was EUR 320 million and the company employs over 1,000 people.

 

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients.  Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.

For more information, please visit www.norgine.com.

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

 

Media Contacts:

Isabelle Jouin, T: +44 (0)1895 453643

Charlotte Andrews, T: +44 (0)1895 453607

Follow us @norgine

 

UK/MOV/0816/0139
August 2016

 

References

 

[1] https://www.medicines.org.uk/emc/